Table 2.
Selected blood biomarkers in SBMA patient cohort
| Blood Biomarker (reference range) | Mean ± std | Abnormal | Abnormal (%) |
|---|---|---|---|
| CK U/l (20–200) | 1167 ± 1003 | 29/30 (↑) | 96.7% |
| CK-MB µg/l (<6.22) | 29.5 ± 24.5 | 24/25 (↑) | 96.0% |
| Troponin T ng/l (<14) | 40.16 ± 30.62 | 22/25 (↑) | 88.0% |
| NT-proBNP pg/l (<85.5) | 100.8 ± 302.4 | 4/25 (↑) | 16.0% |
| Cholesterol mmol/l (<5.0) | 5.75 ± 1.72 | 19/29 (↑) | 65.5% |
| Triglycerides mmol/l (<1.7) | 2.69 ± 3.30 | 16/29 (↑) | 55.2% |
| HDL mmol/l (>1.0) | 1.45 ± 0.40 | 6/28 (↓) | 21.4% |
| LDL mmol/l (<3.0) | 3.51 ± 0.98 | 20/28 (↑) | 71.4% |
| 17OH-Progesteron µg/l (0.05–1.60) | 0.97 ± 0.64 | 4/28 (↑) | 14.3% |
| Androstendion µg/l (0.7–3.6) | 1.67 ± 0.80 | 3/28 (2↓, 1↑) | 10.7% |
| DHEA-Sulfat µg/dl (44.3–3331.0) | 246 ± 140 | 1/28 (↓) | 3.6% |
| FSH IU/l (1.5–12.4) | 7.53 ± 5.35 | 4/28 (↑) | 14.3% |
| LH IU/l (1.70–8.60) | 7.91 ± 3.02 | 8/28 (↑) | 28.6% |
| Estradiol ng/l (11.3–43.2) | 33.6 ± 13.2 | 6/28 (↑) | 21.4% |
| Progesterone µg/l (<0.149) | 0.25 ± 0.23 | 10/28 (↑) | 35.7% |
| SHBG nmol/l (4.0–15.2) | 60.3 ± 21.1 | 8/29 (↑) | 27.6% |
| Testosterone µg/l (1.93–7.40) | 5.59 ± 2.07 | 6/29 (↑) | 20.7% |
| Androgen sensitivity index (ASI) (LH in IU/l × testosterone in nmol/l) (<138) | 44.6 ± 25.9 | 0/28 | 0% |
CK creatine kinase, CK-MB creatine kinase muscle-brain type, DHEA dehydroepiandrosterone, FSH follicle-stimulating hormone, LH luteinizing hormone, SHBG sex-hormone binding globulin